Scoop has an Ethical Paywall
Licence needed for work use Learn More

Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

IRL and Epichem Pty Ltd combine strengths

IRL and Epichem Pty Ltd combine strengths in Australasian alliance

Industrial Research Ltd (IRL) and Epichem Pty Ltd today announced the launch of a strategic alliance designed to provide clients with continuous and seamless services from drug discovery to cGMP production.

The two parties to this memorandum of understanding (MoU) are both providers of high quality products and services in the area of organic chemistry, and possess complementary skills, which will combine to better serve the Australasian pharmaceuticals market.

“It’s important that we make the best use of the capabilities in our region in order to drive biotechnology company development,” says IRL General Manager of Industrial Biotechnologies Dr Richard Furneaux.

IRL’s Carbohydrate Chemistry and GlycoSyn teams have built a world class reputation since 1984 in the chemical synthesis of carbohydrate active pharmaceutical intermediates (APIs), specialist fine chemicals, multi-step small molecule chemistry, dendrimer and peptide chemistry and drug development.

Epichem Pty Ltd, with laboratories in Western Australia and Victoria, are an established supplier of products and services in the field of synthetic and medicinal chemistry, in particular specialising in aromatic and heterocyclic chemistry and the design and synthesis of analogue libraries using parallel chemistry. Epichem also supplies a range of API impurity, degradant and metabolite standards.

“IRL and Epichem Pty Ltd have complementary expertise that is valuable for biotechnology companies in taking their products forward for commercialisation”, says Dr Furneaux.

Advertisement - scroll to continue reading

The alliance’s first collaborative project involves the use of chiral scaffolds in the construction of drug discovery libraries.

“We have a chiral pharmaceuticals FRST programme, co-funded by New Zealand Pharmaceuticals Ltd (NZP), and together we have created a range of chiral scaffolds that can be used in creating drug discovery libraries,” says Dr Furneaux. “Epichem have capability in making these libraries and together we can produce a demonstration of their utility in biological systems.”

ENDS

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.